Participated · Series A · Jun 2026

Syntax Bio develops a CRISPR-based Cellgorithm™ platform intended to program and accelerate stem cell differentiation to enable scalable cell therapies. The company is advancing a pancreatic beta cell therapy candidate for type 1 diabetes and plans to fund preclinical proof-of-concept studies with proceeds from its expanded Series A. Syntax Bio has publicly reported a collaboration with Mayo Clinic, received a grant from Breakthrough T1D, and published peer-reviewed research in Science Advances describing its technology. Financially, the company expanded its Series A to $14.4 million, bringing total funding to over $25 million. Leadership changes accompanying the financing include a CEO who joined in 2025 and new executive, board, and scientific advisory appointments to support translational development and commercialization. The company positions its platform as a way to replace slow, labor-intensive differentiation processes with a programmable approach to generate functional cells at scale.

Participated · Equity · Apr 2026

Lightcast develops the Envisia platform, a benchtop system that captures functional single-cell data using proprietary light-controlled picoliter droplet manipulation to interrogate tens of thousands of droplets with speed and precision. The platform enables sequential single-cell functional screening and is being applied to antibody discovery, cell-cell interaction studies, immunology, oncology, cell therapy, and cell line development. Lightcast has run an early access program with leading pharmaceutical and academic institutions to validate performance and optimize workflows. The company plans a full commercial release of Envisia in 2026, and the recent financing is intended to support assay portfolio expansion, manufacturing and software readiness, and broader commercial rollout. Lightcast was founded in 2019 and is based in Cambridge, UK.

Participated · Equity · Feb 2026

CubaseBio is building a next-generation 3D spatial transcriptomics platform that captures gene expression inside intact specimens through volumetric DNA microscopy. The technology reconstructs three-dimensional proximity maps by embedding molecular networks into samples and decoding them with DNA sequencing, yielding both spatial coordinates and nucleotide-level information in a single readout. By moving beyond traditional 2D tissue sections, the company aims to make spatial biology workflows scalable for drug discovery, disease research, organoid studies and whole-organism profiling. Founded in 2024 by spatial-omics veterans Malte Kuhnemund, Xiaoyan Qian, Toon Verheyen and Paulius Mielinis, the team also includes scientific advisory co-founders Joshua Weinstein and Björn Högberg, pioneers of DNA microscopy. CubaseBio plans to use its newly raised capital to advance core technology development, expand engineering capacity and initiate early commercialization efforts. Financially, the company has secured €5.9 million in blended funding, its first external capital, providing runway to refine the platform and engage pilot customers. No user, revenue or deployment metrics have been disclosed yet.

Participated · Series B · Jan 2026

Precede Biosciences is a precision diagnostics and data company that has built a proprietary, automated assay capable of extracting high-resolution, genome-wide transcriptional information from a single blood draw. The platform integrates this assay with advanced machine-learning analytics, enabling researchers and clinicians to profile target expression and pathway activity—critical biomarkers for drug-, radio- and immune-conjugates and other targeted therapies. By providing a multiplex, minimally invasive alternative to tissue biopsies, the company aims to accelerate drug development and ensure patients receive therapies precisely matched to their disease biology. Current commercial traction is described as “rapidly growing,” driven by partnerships with developers of next-generation precision medicines. The fresh financing brings Precede Bio’s total new capital to $83.5 million, giving the company resources to scale its platform and meet rising demand. An expanded investor base with deep diagnostics-commercialization expertise is expected to support health-system adoption and long-term growth.

Participated · Convertible Note · Jan 2026

Alamar Biosciences is a privately held life-sciences company focused on enabling the earliest detection of disease through precision proteomics. Its proprietary NULISA™ chemistry paired with the ARGO™ HT System delivers ultra-high sensitivity, addressing key limitations of existing protein-analysis technologies. The company positions its platform to unlock broad applications across health and disease, aiming to expand precision medicine and biomarker discovery. Recent capital infusions are being directed toward commercial advancement and scaling of this platform. Leadership additions—including Chief Scientific Officer Dr. Stephen Williams and two new board members—are intended to bolster scientific, operational, and financial execution. Headquartered in Fremont, California, Alamar continues to attract backing from top life-science and crossover investors. While revenue and user metrics are not disclosed, the company’s oversubscribed financings signal strong investor confidence in its growth prospects.